Outlook Therapeutics (NASDAQ:OTLK) issued its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.21, Bloomberg Earnings reports. The business had revenue of $1.07 million during the quarter.
Shares of OTLK traded up $0.05 during trading hours on Friday, reaching $1.33. The company’s stock had a trading volume of 23,962 shares, compared to its average volume of 463,725. Outlook Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.37.
Separately, ValuEngine downgraded Outlook Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.
WARNING: This article was first posted by Fairfield Current and is owned by of Fairfield Current. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.fairfieldcurrent.com/news/2019/02/15/outlook-therapeutics-otlk-posts-earnings-results-beats-estimates-by-0-21-eps.html.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Article: What is the yield curve?
Receive News & Ratings for Outlook Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outlook Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.